Company Overview and News

1
GLYC / GlycoMimetics, Inc. 8-K (Current Report)

2018-05-21 sec.gov
glyc_Current_Folio_8K no exhibits UNITED STATES

 
GlycoMimetics' (GLYC) CEO Rachel King on Q1 2018 Results - Earnings Call Transcript

2018-05-06 seekingalpha
Good morning, and thank you all for joining the GlycoMimetics' call. At this time all participants are in a listen-only mode. [Operator Instructions]

3
GLYC / GlycoMimetics, Inc. 10-Q (Quarterly Report)

2018-05-03 sec.gov
glyc_Current_Folio_10Q Table of Contents

1
GLYC / GlycoMimetics, Inc. 8-K (Current Report)

2018-05-03 sec.gov
glyc_Current_Folio_8K UNITED STATES

 
BRIEF-Glycomimetics Reports Qtrly Loss Per Share Of $0.33

2018-05-03 reuters
* GLYCOMIMETICS INC - AS OF MARCH 31, 2018, GLYCOMIMETICS HAD CASH AND CASH EQUIVALENTS OF $242.6 MILLION AS COMPARED TO $123.9 MILLION AS OF DECEMBER 31, 2017 Source text for Eikon: Further company coverage:

2
GLYC / GlycoMimetics, Inc. DEF 14A

2018-04-13 sec.gov
glyc_Current_Folio_DEF14A SCHEDULE 14A INFORMATION

 
GlycoMimetics: Buy This Dip

2018-04-04 seekingalpha
GlycoMimetics (NASDAQ:GLYC) is a clinical stage biotechnology company with two drug candidates that could gain FDA approval in 2019 and 2021, respectively. Recent developments, including the general decline in pharma stock prices, have made the dip in the price of GlycoMimetics a compelling buy. However, there are risks involved, notably the risk that, despite good preliminary data, one or both of the therapies in the pipeline will fail to generate passable Phase 3 trial data.

 
GLYC / GlycoMimetics, Inc. 424B5 (Prospectus)

2018-03-21 sec.gov
Use these links to rapidly review the document TABLE OF CONTENTS TABLE OF CONTENTS

2
 
GLYC / GlycoMimetics, Inc. 424B5 (Prospectus)

2018-03-19 sec.gov
Use these links to rapidly review the document TABLE OF CONTENTS TABLE OF CONTENTS

2
GlycoMimetics: No Longer ROTY, But Still A Buy

2018-03-08 seekingalpha
While there is always room to improve, I am satisfied with how we handled this one and that readers reaped substantial profits.

 
GLYC / GlycoMimetics, Inc. S-8

2018-03-06 sec.gov
glyc_Current Folio_S8 As filed with the Securities and Exchange Commission on March 6, 2018

2
GLYC / GlycoMimetics, Inc. 10-K (Annual Report)

2018-03-06 sec.gov
glyc_Current_Folio_10K Table of Contents

 
GlycoMimetics' (GLYC) CEO Rachel King on Q4 2017 Results - Earnings Call Transcript

2018-03-06 seekingalpha
Good morning and thank you all for joining GlycoMimetics call. At this time, all participants are in a listen-only mode. Following management's remarks, we will hold a brief question-and-answer session and at that time, the lines will be opened for you. [Operator Instructions]

GLYC: GlycoMimetics Analysis and Research Report

2018-05-07 - Asif

Overview GlycoMimetics is a clinical-stage biotechnology company focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. Glycomimetics are molecules that mimic the structure of carbohydrates involved in important biological processes. The company's proprietary glycomimetics platform is based on its expertise in carbohydrate chemistry and its understanding of the role carbohydrates play in key biological processes. Using this expertise and understanding, GlycoMimetics is developing a pipeline of proprietary glycomimetics designed to inhibit disease-related functions of carbohydrates, such as the roles they play in inflammation, cancer and infection. The company believe this represents an innovative approach to drug discovery to treat a wide range of diseases. Most human proteins are modified by the addition of complex carbohydrates to the surface of the proteins...

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

2018-05-21 - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

2018-05-21 - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...

CUSIP: 38000Q102